Wednesday, March 29, 2023


Biotechnology News Magazine

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Latest Posts

Risk From Pharma Reps Using Unapproved Content and Messaging in the Field Persists, but a Focus on Training Could Be the Answer

ACTO advises Study Reveals 50% of respondents in leadership roles catch incidents of field reps using unapproved content, but a continuous learning culture could eliminate this behavior.

Entrinsic Bioscience® Expands enterade® Brand with Innovative Approach to the Dietary Support of Irritable Bowel Syndrome with Diarrhea (IBS-D

enterade® IBS-D is the first medical food formulated with plant-based amino acids and electrolytes for Irritable Bowel Syndrome with Diarrhea (IBS-D)-

Russell Finex Helps Leading Pharmaceutical Company Meet High Levels Of Demand With The Russell Compact Sieve

To ensure the highest quality final product, the company reached out to Russell Finex for a high-capacity vibrating screen. After assessing the company’s requirements, Russell Finex recommended the Russell Compact Sieve® as the ideal solution for check-screening pharmaceutical powders due to its stainless-steel contact parts, and easy-to-clean strip down design.

How Biotech Businesses Can Benefit from Freelance Experts

Ashmita Das, CEO of open talent platform Kolabtree, shares some of Kolabtree freelancer’s success stories.

GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced it has acquired Intelligent Fingerprinting Limited (IFP), thus expanding the GBS platform of rapid, non-invasive diagnostic testing technologies. In addition, GBS announced it has begun the process of changing its corporate name.

Intelligent Fingerprinting’s unique and proprietary drug screening system is an on-the-spot, 10-minute test that works by analyzing fingerprint sweat to screen for recent drug use. IFP currently detects opioids, cocaine, methamphetamines, benzodiazepines and marijuana use. The non-invasive system consists of a portable reader and single-use disposable cartridges that are used by a range of public sector and commercial customers across applications, including workplaces, drug rehabilitation, criminal justice, and medical examiners. To date IFP has mainly concentrated market development efforts in the United Kingdom through a direct sales force and lead generation team.

As a result of the transaction, GBS has gained access to the full IFP product portfolio, the company’s current customer base which exceeds 200 customers, and its ISO 13485 manufacturing facility in the United Kingdom, which complements GBS’ development of its own facility at the University of Newcastle, Australia. GBS will immediately begin the process of submitting IFP’s CE Mark to the Therapeutic Goods Association of Australia and acting as the sponsor for regulatory approval to begin a direct sales campaign in the first half of 2023.

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Philip Hand, Executive Chairman of Intelligent Fingerprinting, commented, “Intelligent Fingerprinting was founded to provide more effective point of care diagnostic solutions that produce swift and highly accurate results through our proprietary fingerprint sweat-based technology. I am delighted to begin this next phase of our growth with GBS as we look to expand our delivery of comprehensive, non-invasive products to the market while expanding our territorial outreach.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine